You are here

Novo Nordisk

ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus

ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus

Xtalks

oral semaglutide

Flag link:

Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decade

Novo Nordisk CEO Jørgensen aims to leverage diabetes know-how, deals into the new decade

Fierce Pharma

Lars Fruergaard Jorgensen

Flag link:

AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much

AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much

Fierce Pharma

Flag link:

Novo Ventures Sows $25M Into Accelerator to Break Into Illustrious Mass Bio Space

Novo Ventures Sows $25M Into Accelerator to Break Into Illustrious Mass Bio Space

Xconomy

Broad Institute

Flag link:

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Dicerna scores broad, 'rest of liver' deal with Novo Nordisk, bagging $225M in cash to hit some 30 targets with RNAi platform

Endpoints

Flag link:

Novo Nordisk buys rights to NASH drug from Japan’s UBE

Novo Nordisk buys rights to NASH drug from Japan’s UBE

Pharmaforum

Flag link:

Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

Novo Nordisk (NVO) Q3 Earnings Beat Estimates, Revenues Miss

Yahoo/Zacks.com

Flag link:

Novo drops oral GLP-1 analog to focus on next-gen Rybelsus

Novo drops oral GLP-1 analog to focus on next-gen Rybelsus

Fierce Biotech

oral semaglutide

Flag link:

Why Novo Nordisk should buy Uniqure

Why Novo Nordisk should buy Uniqure

EP Vantage

Flag link:

Novo taps bluebird bio for gene-editing tech

Novo taps bluebird bio for gene-editing tech

Fierce Biotech

Flag link:

Novo Nordisk announces obesity digital health tie-up with Noom

Novo Nordisk announces obesity digital health tie-up with Noom

Pharmaforum

Flag link:

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Fierce Pharma

Flag link:

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

Motley Fool

Flag link:

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

Pharmaforum

oral semaglutide

Flag link:

Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus

Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus

Fierce Pharma

oral semaglutide

type 2 diabetes

Flag link:

Novo and Sanofi make case for hypo-reducing insulins at EASD

Novo and Sanofi make case for hypo-reducing insulins at EASD

Pharmaforum

Flag link:

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

Investors Business Daily

oral semaglutide

Flag link:

EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win

EASD: Novo's Ozempic tops Victoza, J&J's Invokana in double head-to-head win

Fierce Pharma

Flag link:

Factbox: Britain's insulin providers prepare for Brexit fallout

Factbox: Britain's insulin providers prepare for Brexit fallout

Yahoo/Reuters

Flag link:

Novo Nordisk and Medtronic to integrate diabetes technology

Novo Nordisk and Medtronic to integrate diabetes technology

Pharmaforum

blood glucose monitoring

Flag link:

Pages